Please login to the form below

Not currently logged in
Email:
Password:

Merck/ Parexel biosimilar alliance

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates

Merck and Parexel have announced a strategic alliance to develop biosimilar candidates.

The agreement will see Parexel, a contract research organisation (CRO) with a focus on the biopharma industry, provide Merck  with access to global clinical development services for designated biosimilar candidates. The biosimilar candidates span several therapy areas.

A dedicated unit of Merck BioVentures,  the division of Merck focused on the development of biosimilars, will also be established within Parexel.

Financial details of the deal were not disclosed.

"Through this agreement, Merck BioVentures has secured broad strategic access to Parexel's proven biosimilar clinical development experience," said Michael Kamarck, president , Merck BioVentures. "This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace."

Josef von Rickenbach, chairman and CEO of Parexel, was also positive about the agreement: "We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide."

13th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 is the world’s largest network of verified doctors with over 6 million members across key markets; our closed and...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...